TP53 and glioblastoma: Because TP53 gain-of-function mutations are also a hallmark of IDH-mutant astrocytomas and are frequently observed in IDH-wildtype GBM without any sarcomatoid features, they may not be sufficient for gliosarcoma pathogenesis.